Abstract
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination and related disorders are often difficult to treat and frequently resistant to change, often rendering conventional modes of treatment (e.g., psychotherapy and pharmacology) unsuccessful. A recent renaissance of psychedelic research shows promise in treating psychopathology with potential for acting on ruminative processes. Though theoretical explanations for the therapeutic effects of psychedelics implicate the reduction of rumination via changes in the default mode network, a limited number of studies have tested this link directly. This mini-review examined the existing empirical research linking psychedelic use and rumination. The results from six studies demonstrate a significant association between psychedelic use and lower levels of rumination, providing evidence that rumination may serve as a key cognitive factor in psychedelic treatment. Further research should explore whether identifying ruminative tendencies and encouraging the practice of disengaging from rumination before the psychedelic treatment session, particularly for those who report high levels of rumination, may result in better adherence to “letting go” during the session. Moreover, due to a possible diminishing effect of therapeutic outcomes after a single psychedelic dosing session, “booster” sessions may provide psychological relief once more; however, financial treatment costs are expectedly high. As such, understanding the role of rumination in psychedelic treatment can be critical for maintenance strategies (e.g., rumination-focused cognitive behavior therapy, mindfulness techniques) in postdosing integration sessions and long-term treatment plans.
Keywords: psychedelics, repetitive negative thinking, rumination, review
Repetitive negative thinking is a perseverative condition involving worrying and/or ruminating over past or present concerns about one’s self, experiences, or feelings.1 Evidence suggests that repetitive negative thinking is a transdiagnostic process that may play a key role in the etiology and comorbidity of psychological disorders, such as negative, self-centered thoughts in depression,2 maladaptive post-event processing in social anxiety,3 and recurrent negative thinking of the traumatic experience and/or its consequences in post-traumatic stress disorder.4 Treatments that target rumination (e.g., rumination-focused cognitive behavior therapy, rf-CBT) produce better outcomes for depression than treatments that do not specifically target rumination (e.g., expressive writing, antidepressant medication).5 Unfortunately, at least half of individuals who receive CBT or other conventional therapies do not respond to treatment.6
Psychedelics are a subtype of hallucinogens that trigger nonordinary mental states with a tendency to ease rigid, maladaptive thoughts and behaviors and have been growing in popularity as an alternative type of treatment.7 A recent renaissance of psychedelic research shows promise in treating numerous psychological disorders and disturbances.8–10 Though many of these studies are early phase clinical trials with small samples, several larger, randomized, double-blind, cross-over clinical trials have demonstrated robust and long-lasting effects.11 For instance, in a study conducted by Griffiths and colleagues12 on 51 cancer patients, 80% of participants continued to show clinically significant reductions in depressed mood and anxiety 6 months following a high dose of psilocybin.
Classical psychedelics (e.g., ayahuasca, N, N-dimethyltryptamine [DMT], lysergic acid diethylamide [LSD], mescaline, psilocybin) are categorized by their agonistic effects on serotonin 5-hydroxytryptamine 2A (5-HT2A) receptors in the brain.13 Though it is not yet understood exactly how the binding of psychedelic compounds to the 5-HT2A brain receptors affects cellular responses and intracellular signaling events,14 these molecular activities often alter visual, auditory, and somatosensory perceptions as well as states of awareness, mood, and cognitive processes without a risk of dependence. Furthermore, psychedelics often occasion mystical experiences, characterized by a user’s sense of interconnectedness and sacredness of all things, containing a noetic and ineffable quality that transcends time and space and induces positive moods.15 Classical psychedelics may also induce a loss of one’s sense of self, also known as ego-dissolution,16 which has been suggested to be an important aspect of the mystical experience by disintegrating the boundaries between one’s self and the world.17
Brain imaging studies have offered some insight into the mechanisms of action.18 For example, a study investigating psilocybin demonstrated increased connectivity between the amygdala and the prefrontal cortex, resulting in a reduction of amygdala hypersensitivity apparent in various psychological disorders.19 In addition, functional magnetic resonance imaging (fMRI) studies on psilocybin20 report a suppression of the posterior cingulate cortex (PCC) in the default mode network (DMN; a higher-level cortical and subcortical network related to self-referential processing, internalization, and long-term narrative processing).21 During a psychedelic experience, the elimination of executive control from the DMN may serve to disrupt habitual cognitive processes, allowing the potential for more adaptive patterns to develop.22 Critically, reduced DMN function is associated with decreases in rumination.23 The psychological benefits experienced from using psychedelics may be attributed to the reduction in DMN function, which in turn disrupts ruminative patterns; however, the effects of psychedelics on ruminative processes have yet to be fully understood. As such, the current article is a state-of-the-science mini-review of the empirical research conducted on the link between repetitive negative thinking and psychedelics.
Method
A thorough search of the literature was conducted using multiple scientific databases (i.e., PsycInfo, Google Scholar, ScienceDirect, EBSCOhost, and MEDLINE) for relevant studies published before February 2024. The following keywords were used for the search: (psychedelic OR ayahuasca OR dimethyltryptamine OR lysergic acid diethylamide OR mescaline OR psilocybin) and (repetitive negative thinking OR rumination OR worry). From the initial search, 44 total studies were gathered from scientific databases that mentioned the link between rumination and psychedelic use (no results were found for worry), and only 20 unique studies remained after removing duplicate studies. Studies were chosen if the link between rumination and psychedelic use was investigated through psychometrically validated measures or qualitative investigations and adhered to recommended review guidelines.24 After a careful assessment of each study, only six studies met criteria.
Results
Please see Table 1 for study characteristics. The literature search yielded a total of six empirical research studies exploring psychedelic use (retrospective self-report or drug administration studies). One study was a qualitative investigation using semistructured interviews, three studies utilized online surveys, two studies were an open-label trial for treatment-resistant depression, and one study was a randomized clinical trial. Two studies used data from participants enrolled in the same open-label trial.
Table 1.
Qualified Studies for the Mini-Review
| Authors, year | Psychedelic type/study design (N) | Participants | Measure of rumination | Primary findings |
|---|---|---|---|---|
| Barba et al., 202025 | psilocybin; randomized clinical trial; control group using escitalopram (n = 59) |
Psilocybin administered group:
|
Ruminative Response Scale (RRS; Treynor et al., 2003) | Rumination scores were lower compared to baseline and six-weeks after the therapeutic dose; Mean reduction: 12.8 |
| Escobar et al., 201526 | ayahuasca; online survey (n = 110) |
|
The Rumination-Reflection Questionnaire (RRQ; Trapnell & Campbell, 1999) | Rumination scores were geometrically further away from ayahuasca church-goers in a Structure Similarity Analysis |
| Fauvel et al., 202127 | various psychedelic types; online survey (n = 164) |
|
Rumination Response Scale (RRS; Treynor et al., 2003) | Rumination scores were lower after a psychedelic experience; Cohen’s d = −0.84 |
| Mertens et al., 202028 | psilocybin; open-label trial (n = 19) |
|
Ruminative Response Scale (RRS; Treynor et al., 2003) | Rumination scores were lower one week and three months after the therapeutic dose compared to baseline; Mean reduction = 21.58 and 15.90, respectively |
| Orłowski et al., 202129 | various psychedelic types; online survey (n = 2,561) |
Psychedelic users group:
|
Polish translation of the Reflection Rumination Questionnaire (RRQ; Trapnell & Campbell, 1999; Radoń, 2014) | Lower rumination scores were associated with psychedelic use; F(3, 2523) = 6.15 |
| Watts et al., 201730 | psilocybin; open-label trial (n = 20) |
|
Thematic analysis of semi-structured interviews | Participants reported ruminating much less after the therapeutic dose |
The following databases were used: PsycInfo, Google Scholar, ScienceDirect, EBSCOhost, MEDLINE. Keywords included: psychedelic OR ayahuasca OR dimethyltryptamine OR lysergic acid diethylamide OR mescaline OR psilocybin) and (rumination OR worry OR repetitive negative thinking).
Psilocybin
Three of the six identified articles examined psilocybin. In the Barba et al.25 randomized clinical trial, participants with moderate to severe major depressive disorder were randomized into one of two groups: (1) participants in the psilocybin group (n = 30) had dosing sessions of 25 mg followed by placebo capsules daily for three weeks for a total of two dosing sessions with three weeks between dosing sessions and (2) participants in the escitalopram group (a selective serotonin reuptake inhibitor; n = 29) took 1 mg of psilocybin at both dosing sessions followed by 10 and 20 mg of escitalopram daily for three weeks each time, respectively. An integration session was conducted the day after each dosing session. A reduction in rumination scores was found among participants in the psilocybin group, as measured by the Ruminative Response Scale (RRS),31 at the 6-week follow-up period compared to baseline measurements taken 1 week before the first dosing session. Participants in the escitalopram group did not show any significant differences in rumination scores. However, when analyses were split between responders (i.e., participants who evidenced 50% or more reduction of their depressive symptoms, 70% of the psilocybin group, and 48% of the escitalopram group) and nonresponders (i.e., participants who evidenced less than 50% reduction of their depressive symptoms), a significant decrease in rumination scores was observed for both psilocybin and escitalopram responders.
In the Mertens et al.28 open-label trial, 19 participants underwent two psilocybin-assisted therapy sessions 1 week apart; the first dosing session included 10 mg as a test dose, followed by 25 mg as a therapeutic dose. An integration session was conducted the day after the therapeutic dose. Baseline fMRI scans were taken while participants engaged in an emotional face paradigm (i.e., participants were shown images of fearful, neutral, or happy faces) before the test dose as well as the next morning after the therapeutic dose and before the integration session. Findings indicated that rumination scores (as indexed by the RRS)31 were lower 1 week and 3 months after the therapeutic dose compared to baseline. Scores increased slightly from 1 week to 3 months, though were not significantly different and remained significantly lower than baseline scores. Furthermore, the results of the fMRI scans revealed decreased functional connectivity between the right amygdala and the ventromedial PFC (a central component of the DMN)32 during the emotional face paradigm after the therapeutic dose, and critically, lower connectivity was associated with less rumination 1 week later.
In a third study by Watts et al.,30 20 participants partook in a semistructured interview 6 months after their participation in an open-label trial of psilocybin for treatment-resistant depression (relevant results from the open-label trial are reported above).28 These participants engaged in a low-dose session with 10 mg of psilocybin and a high-dose session with 25 mg of psilocybin, 7 days apart. Notably, when speaking on their experience of depression before the dosing sessions, every participant described suffering from rumination, which the authors describe as “automatic single-tracked negative thoughts.” Participants described elevated levels of rumination, engaging in rumination for long amounts of time, and daily dysfunction. Multiple participants reported ruminating much less after the psilocybin treatment. For example, one participant stated:
My mind works differently [now]. I ruminate much less, and my thoughts feel ordered, contextualized. Rumination was like thoughts out of context, out of time; now my thoughts feel like they make sense, with context and logical flow.
However, one participant noted that their rumination had not improved. Though the researchers did not specify how many participants experienced a decrease in levels of rumination after the psilocybin treatment, researchers concluded that participants who began ruminating again after a few months still reported feeling much better after the treatment.
Ayahuasca
Only one of the six identified articles examined ayahuasca. In Escobar et al.,26 participants in a convenience sample (n = 110) from three ayahuasca churches in Pernambuco, Brazil, completed the Rumination-Reflection Questionnaire.33 The results from the study demonstrated that reflection scores (i.e., an epistemic interest or curiosity in self-exploration) were higher than rumination scores for churchgoers across all three ayahuasca churches. Furthermore, a Structural Similarity Analysis (SSA) was used to graphically demonstrate associations between variables as geometrical distances in a scalogram. The results from the SSA revealed a relative proximity of elevated rumination to various psychological indices such as stress, anxiety, depression, and hopelessness and a relative distance away from ayahuasca churches, with the exception that rumination was significantly elevated in one church.
Multiple psychedelic types
Two of the six identified articles examined the use of multiple psychedelic types. In Fauvel et al.,27 psychedelics users (i.e., psilocybin/magic mushrooms/truffles, LSD/LSD derivatives or analogues [e.g., 1P-LSD, ALD-52], ayahuasca, DMT/5-MeO-DMT, mescaline [from peyote or san pedro], iboga/ibogaine, salvia/salvinorin) completed online questionnaires (n = 164). Participants gave retrospective reports of their rumination tendencies using the RRS26 before and after their single most significant psychedelic experience. The results revealed lower rumination scores following the psychedelic experience. Furthermore, an analysis of indirect effects found that rumination explained significant variance in the link between the level of psychological insights and decreases in depression, anxiety, and stress scores.
Orlowski et al.29 recruited both classical psychedelics (i.e., LSD, psilocybin mushrooms, synthetic psilocybin, DMT, changa [a blend of DMT and a monoamine oxidase inhibitor], ayahuasca, mescaline, and derivatives of classical psychedelics) and nonpsychedelics users (n = 2,561) via an online survey. Participants completed the polish translation of the Rumination-Reflection Questionnaire.34 The results indicated that lifetime psychedelic use was significantly associated with lower rumination scores. Furthermore, an analysis of indirect effects found that ego dissolution accounted for a significant amount of variance in the link between lifetime psychedelic use and lower rumination.
Discussion
Although several theoretical explanations for the therapeutic potential of psychedelics involve reduced rumination as a mechanism of action,35 only six empirical studies have tested this link. The limited data available suggest that psychedelic use across multiple types, either clinically or naturalistically administered, is associated with reduced self-reported rumination in the short term. Although not observed among responders alone, when examining the full sample preliminary findings suggest that two therapeutic doses of psilocybin may be more efficacious for reducing rumination than the conventional daily dose of escitalopram.25 Moreover, researchers found significant reductions in thought suppression at the 6-week follow-up for the psilocybin group that were not found among escitalopram responders. Therefore, escitalopram responders may ruminate less yet still engage in thought suppression. Findings from brain imaging scans suggest that decreased amygdala-prefrontal connectivity may play an important role.28 As expected, rumination has been implicated as a potential mechanism that leads to decreases in depression, anxiety, and stress,27 and an experience of ego dissolution may precede rumination in the causal sequence of events.29 Collectively, however, more research is warranted.
Sampling and methodological considerations
The limited numbers of open-label and clinical trial studies assessing psychedelics and rumination in this mini-review have relatively small sample sizes and exclusively administer psilocybin over other psychedelics. Indeed, two of the included studies use data from participants enrolled in the same open-label trial. Furthermore, studies with large sample sizes in the current mini-review are limited by their cross-sectional and retrospective self-report designs. Randomized placebo-controlled clinical trials and brain imaging approaches along with longitudinal studies and administration-based experimental designs may better handle questions of temporal relations. Furthermore, half of the samples in the current review are clinical samples, and half of the samples are community-recruited. The difference in samples is important to consider; indeed, psychedelic treatment imbedded in a rigorous psychotherapeutic protocol may result in different treatment effects than either religious or recreational use of psychedelics.
Future directions
Analytic models project that most states in the United States will legalize psychedelics by 2034–2037.36 Thus, it is crucial for researchers to explore the practical implementation of psychedelic treatment within the framework of current clinical settings and established treatment models.37 Indeed, the pursuit of optimizing therapeutic methods opens new avenues for clinical and scientific investigation, with a need to establish best practices and gold standards.38 Attention given to individual differences in rumination may be a key factor that affects the course of psychedelic treatment.
Though the current standard of care for psychotherapeutic protocols includes three phases (preparation, psychedelic, and integration sessions)39 and typically involves a nondirective approach during the psychedelic dosing phase (i.e., the participant wears eyeshades, listens to preselected music with headphones, and turns their attention inward), protocols for preparation and integration sessions show greater variability. Studies demonstrate a diverse selection of evidence-based therapies.40–42 Furthermore, the number and length of preparation, treatment, and integration sessions also varies across protocols, with some studies providing two psilocybin treatment sessions with varying doses (10 mg and 25 mg one week later) and three integration sessions between psilocybin administration.43 Due to the considerable variation, contemporary research has yet to identify specific factors that maximize the effectiveness of psychotherapeutic protocols and sustain treatment effects.44
Targeting specific ruminative processes for individuals with high levels of rumination may benefit the course of psychedelic treatment. During preparation sessions, therapists may teach participants cognitive techniques (e.g., mindfulness, rf-CBT) and encourage the rehearsing of those techniques before treatment sessions. Consequently, these cognitive techniques may serve as practical tools for the participant during the psychedelic treatment session, similar to preparation instructions of “letting go” and “surrender” given in several study protocols.45 This practice may help the participant explore a challenging psychedelic experience with less psychological resistance. Though feeling stuck in thought loops that feel uncontrollable and as though they are never-ending is a common characteristic of challenging psychedelic experiences,46 challenging experiences during a psychedelic experience may be therapeutically beneficial,47 particularly if the participant gains personal insight and/or experiences an emotional breakthrough following the challenging experience.48 The emphasis on identifying ruminative tendencies and the practice of disengaging from rumination before the psychedelic treatment session may result in better adherence to “letting go” during the session and, perhaps, even lead to successful encounters with challenging experiences.49 Lastly, during integration sessions, bringing attention to any reductions in rumination elicited by the psychedelic experience may encourage the participant to continue the practice and possibly sustain long-term effects.
Though psychedelic treatment has shown to offer individuals tremendous psychological relief, psychopathological symptoms may remit months or years later when the participant returns to similar ecological systems (e.g., troubling familial dynamics, work stressors, broader political concerns). Though “booster” sessions may provide psychological relief once more, financial treatment costs are expectedly high.50 Future studies should examine the effectiveness of maintenance strategies, such as adopting a cognitive technique (e.g., mindfulness techniques that specifically reduce repetitive negative thinking) that can be used before and after treatment sessions.
Authors’ Contributions
B.R.: Conceptualization, Investigation, and Writing—original draft. H.B.: Writing—review and editing, and Supervision. A.R.: Writing—review and editing, and Supervision. A.B.: Writing—review and editing, and Supervision. L.T.: Writing—review and editing.
Authors Disclosure Statements
The authors report no conflicts of interest.
Funding Information
No funding was received to assist with the preparation of this article.
References
- 1. Ehring T, Watkins ER. Repetitive negative thinking as a transdiagnostic process. Int J Cogn Ther 2008;1(3):192–205; doi: 10.1521/ijct.2008.1.3.192 [DOI] [Google Scholar]
- 2. Berman MG, Peltier S, Nee DE, et al. Depression, rumination and the default network. Soc Cogn Affect Neurosci 2011;6(5):548–555; doi: 10.1093/scan/nsq080 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Rachman S, Grüter-Andrew J, Shafran R. Post-event processing in social anxiety. Behav Res Ther 2000;38(6):611–617; doi: 10.1016/s0005-7967(99)00089-3 [DOI] [PubMed] [Google Scholar]
- 4. Michael T, Halligan SL, Clark DM, et al. Rumination in posttraumatic stress disorder. Depress Anxiety 2007;24(5):307–317; doi: 10.1002/da.20228 [DOI] [PubMed] [Google Scholar]
- 5. Spinhoven P, Klein N, Kennis M, et al. The effects of cognitive-behavior therapy for depression on repetitive negative thinking: A meta-analysis. Behav Res Ther 2018;106:71–85; doi: 10.1016/j.brat.2018.04.002 [DOI] [PubMed] [Google Scholar]
- 6. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014;156:1–7; doi: 10.1016/j.jad.2013.10.043 [DOI] [PubMed] [Google Scholar]
- 7. Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry 2018;30(4):291–316; doi: 10.1080/09540261.2018.1486289 [DOI] [PubMed] [Google Scholar]
- 8. Hendricks PS, Thorne CB, Clark CB, et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 2015;29(3):280–288; doi: 10.1177/0269881114565653 [DOI] [PubMed] [Google Scholar]
- 9. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014;28(11):983–992; doi: 10.1177/0269881114548296 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med 2019;49(4):655–663; doi: 10.1017/S0033291718001356 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 2017;42(11):2105–2113; doi: 10.1038/npp.2017.84 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30(12):1181–1197; doi: 10.1177/0269881116675513 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Nichols DE, Nichols CD. The pharmacology of psychedelics. In: Hand-book of Medical Hallucinogens. Guilford Press: 2021; pp. 1. [Google Scholar]
- 14. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101(2):131–181; doi: 10.1016/j.pharmthera.2003.11.002 [DOI] [PubMed] [Google Scholar]
- 15. Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Curr Top Behav Neurosci 2018;36:393–430; doi: 10.1007/7854_2017_474 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Stoliker D, Egan GF, Friston KJ, et al. Neural mechanisms and psychology of psychedelic ego dissolution. Pharmacol Rev 2022;74(4):876–917; doi: 10.1124/pharmrev.121.000508 [DOI] [PubMed] [Google Scholar]
- 17. MacLean KA, Leoutsakos JM, Johnson MW, et al. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 2012;51(4):721–737; doi: 10.1111/j.1468-5906.2012.01685.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Erritzoe D, Timmermann C, Godfrey K, et al. Exploring mechanisms of psychedelic action using neuroimaging. Nat Mental Health 2024;2(2):141–153; doi: 10.1038/s44220-023-00172-3 [DOI] [Google Scholar]
- 19. Roseman L, Demetriou L, Wall MB, et al. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 2018;142:263–269; doi: 10.1016/j.neuropharm.2017.12.041 [DOI] [PubMed] [Google Scholar]
- 20. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109(6):2138–2143; doi: 10.1073/pnas.1119598109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Brandman T, Malach R, Simony E. The surprising role of the default mode network in naturalistic perception. Commun Biol 2021;4(1):79; doi: 10.1038/s42003-020-01602-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci Rep 2017;7(1):13187; doi: 10.1038/s41598-017-13282-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Coutinho JF, Fernandesl SV, Soares JM, et al. Default mode network dissociation in depressive and anxiety states. Brain Imaging Behav 2016;10(1):147–157; doi: 10.1007/s11682-015-9375-7 [DOI] [PubMed] [Google Scholar]
- 24. Sirriyeh R, Lawton R, Gardner P, et al. Reviewing studies with diverse designs: The development and evaluation of a new tool. J Eval Clin Pract 2012;18(4):746–752; doi: 10.1111/j.1365-2753.2011.01662.x [DOI] [PubMed] [Google Scholar]
- 25. Barba T, Buehler S, Kettner H, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open 2022;8(5):e163; doi: 10.1192/bjo.2022.565 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Escobar JA, Roazzi A, de Souza BC, et al. Mediation of self-rumination on mental health related aspects: a multidimensional approach. In: Facet Theory: Searching for Structure in Complex Social, Cultural and Psychological Phenomena. UFPE; 2015; pp. 432–51. [Google Scholar]
- 27. Fauvel B, Strika-Bruneau L, Piolino P. Changes in self-rumination and self-compassion mediate the effect of psychedelic experiences on decreases in depression, anxiety, and stress. Psychol Conscious 2023;10(1):88–102; doi: 10.1037/cns0000283 [DOI] [Google Scholar]
- 28. Mertens LJ, Wall MB, Roseman L, et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol 2020;34(2):167–180; doi: 10.1177/0269881119895520 [DOI] [PubMed] [Google Scholar]
- 29. Orłowski P, Ruban A, Szczypiński J, et al. Psychedelics use predicts more positive emotional reactivity and diminished outward-focused self-consciousness: The mediating role of ego dissolution and mystical experiences. J Psychopharmacol 2022;36(8):987–1000; doi: 10.1177/02698811221089034 [DOI] [PubMed] [Google Scholar]
- 30. Watts R, Day C, Krzanowski J, et al. Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanistic Psychol 2017;57(5):520–564; doi: 10.1177/0022167817709585 [DOI] [Google Scholar]
- 31. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: A psychometric analysis. Cog Ther Res 2003;27:247–259; doi: 10.1023/A:1023910315561 [DOI] [Google Scholar]
- 32. Lopez-Persem A, Verhagen L, Amiez C, et al. The human ventromedial prefrontal cortex: Sulcal morphology and its influence on functional organization. J Neurosci 2019;39(19):3627–3639; doi: 10.1523/JNEUROSCI.2060-18.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Trapnell PD, Campbell JD. Private self-consciousness and the five-factor model of personality: Distinguishing rumination from reflection. J Pers Soc Psychol 1999;76(2):284–304; doi: 10.1037/0022-3514.76.2.284 [DOI] [PubMed] [Google Scholar]
- 34. Radoń S. Kwestionariusz Ruminacji-Refleksyjności (polska adaptacja The Rumination-Reflection Questionnaire).
- 35. Husain MI, Ledwos N, Fellows E, et al. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Front Psychiatry 2022;13:1076459; doi: 10.3389/fpsyt.2022.1076459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Siegel JS, Daily JE, Perry DA, et al. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry 2023;80(1):77–83; doi: 10.1001/jamapsychiatry.2022.4101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Yaden DB, Johnson MW, Griffiths RR, et al. Psychedelics and consciousness: Distinctions, demarcations, and opportunities. Int J Neuropsychopharmacol 2021;24(8):615–623; doi: 10.1093/ijnp/pyab026 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Feduccia A, Agin-Liebes G, Price CM, et al. The need for establishing best practices and gold standards in psychedelic medicine. J Affect Disord 2023;332:47–54; doi: 10.1016/j.jad.2023.03.083 [DOI] [PubMed] [Google Scholar]
- 39. Brennan W, Kelman AR, Belser AB. A Systematic review of reporting practices in psychedelic clinical trials: Psychological support, therapy, and psychosocial interventions. Psychedelic Medicine 2023;1(4):218–229; doi: 10.1089/psymed.2023.0007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 2015;29(3):289–299; doi: 10.1177/0269881114565144 [DOI] [PubMed] [Google Scholar]
- 41. Horton DM, Morrison B, Schmidt J. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Am J Psychother 2021;74(4):140–149; doi: 10.1176/appi.psychotherapy.20200055 [DOI] [PubMed] [Google Scholar]
- 42. O’Donnell KC, Mennenga SE, Owens LT, et al. Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. Contemp Clin Trials 2022;123:106976; doi: 10.1016/j.cct.2022.106976 [DOI] [PubMed] [Google Scholar]
- 43. Carhart-Harris RL, Bolstridge M, Day CM, et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl) 2018;235(2):399–408; doi: 10.1007/s00213-017-4771-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Cavarra M, Falzone A, Ramaekers JG, et al. Psychedelic-assisted psychotherapy—A systematic review of associated psychological interventions. Front Psychol 2022;13:887255; doi: 10.3389/fpsyg.2022.887255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Wolff M, Evens R, Mertens LJ, et al. Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry 2020;11:5; doi: 10.3389/fpsyt.2020.00005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Barrett FS, Bradstreet MP, Leoutsakos JM, et al. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 2016;30(12):1279–1295; doi: 10.1177/0269881116678781 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Gashi L, Sandberg S, Pedersen W. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy 2021;87:102997; doi: 10.1016/j.drugpo.2020.102997 [DOI] [PubMed] [Google Scholar]
- 48. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 2017;8:974; doi: 10.3389/fphar.2017.00974 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci 2020;15:92–102; doi: 10.1016/j.jcbs.2019.12.004 [DOI] [Google Scholar]
- 50. Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry 2022;13:1025726; doi: 10.3389/fpsyt.2022.1025726 [DOI] [PMC free article] [PubMed] [Google Scholar]
